With the most approved indications and the widest coverage of medical insurance, Hengrui Pharmaceuticals strives to promote PD-1 to benefit patients

Recently, information from the State Food and Drug Administration showed that another domestically produced PD-1 was approved for marketing
.

So far, the number of PD-1s on the domestic market has reached 7 models, of which 2 are imported and 5 are domestically produced

Speaking of PD-1, Hengrui Medicine cannot be ignored
.

In July 2019, Hengrui Medicine's blockbuster innovative drug PD-1 carrelizumab was launched and achieved sales of approximately 2 billion yuan that year

However, public data shows that there are currently more than 100 domestic companies developing PD-1 products, and more than 50 PD-1 models have entered the clinical stage
.

It can be said that PD-1 has become one of the most crowded tracks in the industry

However, as Sun Piaoyang, Chairman of Hengrui Pharmaceuticals, once pointed out, “Hengrui’s model is to find a good medicine, then make it well and deliver it to the patient to benefit the patient
.

” In other words, compared to In pursuit of the profitability of PD-1 indefinitely, Hengrui Pharmaceuticals pays more attention to the benefits that PD-1 can bring to patients as a high-quality innovative drug

After understanding this, looking back at the various actions of Hengrui Medicine in the development and promotion of PD-1 in recent years, we will also understand its unique advantages
.

At the beginning of its launch, Hengrui Medicine's Karelizumab was approved for Hodgkin's lymphoma
.

In 2020, driven by the strong clinical research and development capabilities of Hengrui Medicine, carrelizumab ushered in the indication-intensive harvest period.

In the first half of 2021, Hengrui Medicine Carrelizumab has been approved for second-line and above nasopharyngeal carcinoma and first-line nasopharyngeal carcinoma two new indications, of which the first-line nasopharyngeal carcinoma indication is the first approved in the world First-line indications for nasopharyngeal carcinoma
.

So far, carrelizumab has been approved for 6 indications, further consolidating its position of "the most approved indications for domestic PD-1"

In terms of medical insurance coverage, all the four approved indications of carrelizumab at the end of 2020 have been included in the latest version of China's national medical insurance catalog
.

It has become the PD-1 product with the widest coverage of domestic medical insurance, and is the only immunotherapy drug that can be reimbursed by medical insurance among the three major cancer types of lung cancer, liver cancer and esophageal cancer

It can be seen from the two aspects of indications and medical insurance coverage that Hengrui Medicine’s PD-1 product is the closest to the patient: compared to the single-indication PD-1 product, carrelizumab can be used for a wider range of cancer patients Group: After entering the national medical insurance catalogue, the unit price of carrelizumab dropped by more than 85%, which greatly eased the economic pressure of patients
.

It can be said that carrelizumab is almost the ultimate in continuously improving the accessibility and affordability of innovative drugs

For this reason, Hengrui Medicine Carrelizumab is recognized by many patients and medical institutions
.
In the first half of this year, the Jiangsu Provincial Medical Security Bureau included 13 kinds of nationally negotiated anti-cancer special drugs such as Carrelizumab into the provincial special drug management scope, and it was fully implemented on April 15
.
After being included in the provincial special medicine management scope, even if some hospitals have time to introduce carrelizumab and other national anti-cancer drugs in the future, patients in Jiangsu Province can still buy these life-saving drugs from designated special medicine medical insurance pharmacies and enjoy them.
The medical insurance reimbursement ratio ranges from 6-9%
.
Many clinicians have called for more national anti-cancer drugs to speed up access to more hospitals, so that doctors and nurses can carry out full-course standardized treatment for cancer patients
.

While continuously benefiting Chinese cancer patients, Hengrui Medicine also actively promotes carrelizumab to the world
.
At present, the international multi-center phase III study of carrelizumab combined with apatinib for the treatment of advanced liver cancer has completed overseas enrollment, and the preparations for the submission of the US FDA BLA/NDA have been initiated
.
Based on this research, carrelizumab has obtained the U.
S.
FDA orphan drug qualification for the treatment of advanced hepatocellular carcinoma indications.
It is expected to enjoy certain policy support in subsequent research and development and commercialization, which will make its overseas market goal one step closer
.

As an innovative drug originally developed by China, Carrelizumab has always focused on the high incidence of malignant tumors in China
.
It is hoped that Carrelizumab can benefit more cancer patients in the future and make greater contributions to the global fight against cancer
.